Pomerantz LLP is investigating Beam Therapeutics and some of its executives for potential securities fraud following a press release on September 8, 2026. The release shared updated clinical trial data for BEAM-302, a treatment for alpha-1 antitrypsin deficiency, noting safety issues including transient liver enzyme elevations. This news caused Beam's stock to fall nearly 10% in one day. The investigation could lead to a class action lawsuit if wrongdoing is found.
The story concerns Beam Therapeutics Inc. For readers following the health sector, here is Pluang's market snapshot as of Sep 17, 2026 21:11 WIB: Among 91 health-sector US stocks priced on Pluang, 59 rose and 31 fell today. Notably, BioNano Genomics Inc (BNGO) gained 9.27% to USD 1.65 with a typical hold time of 49 days, while Novavax Inc (NVAX) rose 8.77% to USD 10.17, attracting 100% buy order activity and a longer hold time of 59 days. Meanwhile, 10X Genomics Inc (TXG) increased 8.02% to USD 78.51 with balanced buy-sell orders and the longest hold time of 94 days among these movers.
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Randstad reported revenue and earnings that exceeded expectations, driven by improving business trends and key labor markets. This positive performance signals momentum in the employment services sector. RBC Capital maintained a 'Sector Perform' rati...
MSC Industrial Supply reported strong Q4 results with revenue rising 10.3% year-over-year to about $1.08 billion, surpassing estimates. Adjusted earnings per share increased to $1.45 from $1.09, also beating expectations. Full-year sales grew 6.4% to...
